Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. (CELU), a Delaware corporation, filed this Current Report on Form 8-K on November 25, 2024. The filing discloses the entry into a Material Definitive Agreement involving a private placement of debt and equity securities.
Key Financial Metrics and Transaction Details
The Company entered into a securities purchase agreement to sell unsecured senior convertible notes and warrants with an aggregate original principal amount of up to $1,000,000. As of the filing date, $500,000 in Notes and Warrants had been issued and sold.
- Debt Instrument: Unsecured senior convertible notes with an 8% annual interest rate (increasing to 10% upon default) and a one-year maturity.
- Conversion Terms: Convertible at the purchaser's option upon default at $2.85 per share or the price of a subsequent financing (minimum $2.5M gross proceeds), subject to a $1.00 floor price.
- Warrants: Purchaser warrants are immediately exercisable with a 5-year term at an exercise price of $2.85 per share, subject to a one-time reset upon a subsequent financing.
- Placement Agent Fees: Madison Global Partners, LLC received a 7% cash fee, a 1% non-accountable expense fee, a $25,000 retainer, and legal expense reimbursement up to $75,000. Additionally, the Company issued placement agent warrants equal to 7% of proceeds at 125% of the offering price.
- Use of Proceeds: Working capital and general corporate purposes.
Note: This filing does not provide revenue, profit, cash flow, or margin data as it reports a specific financing event rather than periodic financial results.
Material Changes and Covenants
The transaction introduces new debt obligations and potential equity dilution. The Notes include customary negative covenants restricting the Company's ability to incur additional indebtedness, pay dividends, or grant security interests in assets without permission.
Outlook, Risks, and Contingencies
The securities were issued under exemptions from registration (Section 4(a)(2) and Rule 506(b)). The filing notes that the securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption. The Company is classified as an emerging growth company.
Key Facts for Investor Verification
- Verify the total amount of capital raised under the $1,000,000 facility beyond the initial $500,000 disclosed.
- Monitor the Company's ability to repay the 8% interest-bearing notes within the one-year maturity period.
- Assess the potential dilution impact from the conversion of notes and the exercise of purchaser and placement agent warrants.
- Review the specific negative covenants in the Purchase Agreement to understand restrictions on future financing or operational flexibility.